阐述血小板活化过程的相关信号转导，并对临床已用和正在研发的抗血小板聚集药物以及相关的中药活性成分进行总结。结果表明，随着血小板活化信号转导通路的不断阐明，可能的治疗干预靶点也逐渐被揭示。目前抗血小板治疗的药物主要是化学单体，针对血小板活化过程的某一个靶点进行干预，进而到达到抗血小板聚集的目的，但是存在抗血小板效果不佳、出血及过敏反应等缺陷。建议针对不同途径的靶点进行药物干预，有针对性地联合用药，以减少出血并发症的发生率。同时要加强中药活性成分抗血小板治疗的研究，为新抗血小板聚集药物的研究开发提供思路。

In this study，we discuss the signaling transduction during platelet activation，and review the active components of antiplatelet Chinese medicine which have been used clinically or are under investigation. The results of articles review showed that with the clarification of signaling transduction during platelet activation，the possible therapeutic target has gradually been revealed. Currently，the main antiplatelet agents used clinically are chemical monomer with a single target，which is prone to increase the risks of bleeding and irritability in addition to low efficacy. Targets of components from traditional Chinese medicine with anti-platelet aggregation effect should be specified which may increase their clinical application. Combination of traditional Chinese and western medicine may improve the efficacy and reduce the bleeding risk of currently used anti-platelet drugs. Moreover，new drugs or cocktail of approved drugs specially targeting multi-steps in the activation of platelet signaling pathways with high efficacy but low side-effect should be developed.

R285.5

国家自然科学基金重点项目（U1032604）；教育部高等学校博士学科点专项科研基金优先发展领域项目（20123107130002）；上海市教委科研创新重点项目（13ZZ099）。